Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing

Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing

NOVATO, Calif., Dec. 20, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical
Inc., a biotechnology company focused on the development of treatments for
rare and ultra-rare genetic disorders, today announced the successful
completion of a $75 million Series B round financing led by Adage Capital
Partners, LP. Joining Adage as new investors in this financing are mutual
funds and separate account clients advised by T. Rowe Price Associates, Inc.,
Jennison Associates LLC (on behalf of clients), funds and accounts under
management by subsidiaries of BlackRock, Inc., Sanofi-Genzyme BioVentures^1,
Shire plc and additional blue chip public market funds.Existing investors,
TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures also
participated in the transaction.

Ultragenyx plans to use the proceeds from the financing primarily to advance
development of the company's lead clinical-stage programs, UX001 and UX003,
and other undisclosed programs. UX001 is a potential substrate replacement
therapy for hereditary inclusion body myopathy currently being investigated in
a fully enrolled, randomized placebo-controlled Phase 2 clinical study with
results anticipated in 2013.UX003 is a recombinant enzyme replacement therapy
intended for the treatment of mucopolysaccharidosis type 7 (MPS 7), which will
enter a Phase 1/2 clinical study in MPS 7 patients in 2013. The company
intends to continue to expand its pipeline through the potential in-licensing
of additional products.

"We welcome the participation of such highly regarded public market and
strategic investors in this pivotal financing," said Eran Nadav, PhD, Managing
Director at TPG Biotech and Chairman of the Board of Ultragenyx. "Ultragenyx,
led by a distinguished team experienced in rare disease drug development, is
building a world-class orphan drug company with a rich pipeline of
transformative therapeutics."

"We deeply appreciate the support of all our investors, new and existing, and
their confidence in our ability to find and efficiently develop compelling new
treatments for devastating rare genetic disorders," said Emil D. Kakkis, MD,
PhD, Chief Executive Officer and Founder of Ultragenyx. "This financing
transaction is critical to expanding our efforts to deliver profound novel
therapies that benefit even more rare disease patients." 

Cowen and Company served as financial advisor on the financing.Ropes & Gray
LLP served as legal advisor.

About Ultragenyx

Ultragenyx is a privately held, development-stage biotechnology company
committed to bringing to market life-transforming therapeutics for patients
with rare and ultra-rare metabolic genetic diseases.The company focuses on
diseases for which the unmet medical need is high, the biology for treatment
is clear, and for which there are no effective treatments.

The company is led by a management team experienced in the development and
commercialization of rare disease therapeutics.Ultragenyx' strategy is
predicated upon time and cost-efficient drug development, with the goal of
delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at
www.ultragenyx.com.

^1 Sanofi-Genzyme BioVentures is a successor fund to Genzyme Ventures, which
has been re-named to reflect an expanded strategic investment focus on areas
of interest to both Sanofi and Genzyme. 

CONTACT: Ultragenyx Pharmaceutical Inc.
         For Media, Bee Nguyen
         For Investors, Shalini Sharp
         415-483-8800
 
Press spacebar to pause and continue. Press esc to stop.